BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 05 nov, 2010
    BioInItaly Investment Forum and Intesa Sanpaolo Start-Up Initiative to be held in Milan from March 16 to March 17, 2011
    Eurand Presents Data on ZENPEP without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients with CF and Pancreatic Insufficiency
    PolyTherics moves lead candidate into development and manufacturing with DSM BioSolutions
    MolMed starts a randomised Phase II trial of NGR-hTNF in a new indication, soft tissue sarcomas
  • 20 ott, 2010
    MolMed: NGR-hTNF among the “Top 10 most interesting oncology projects to watch”
    NAICONS leads two projects awarded more than 3M€ for the development of two new promising antibiotics
    Aptuit and Siena Biotech Announce Strategic Relationship in Italy: new models of R&D help to advance compounds in key disease areas
  • 01 lug, 2010
    SOFIMAC PARTNERS launches the fund Technology and Health 1 with first Italian investment
    Axxam and partners awarded EUR 1.5 million by the Regione Lombardia (Metadistretti) to support a drug discovery project on a new key metabolic enzyme
    MolMed leads a project awarded a € 1.4 million grant by Regione Lombardia for optimisation of TK therapy manufacturing process
    Bio3 Research exercised an option for exclusive license from Protelica, Hayward, California, for mimic-antibody antagonists to HMGB1
    MolMed Share Capital Increase via Pre-emptive Rights Offering
    Axxam and Lonza Announce the Signing of a License Agreement for the Use of Axxam’s Photoproteins in Lonza’s Calcium Biosensors
    Presentation of preclinical data for NicOx’s ophthalmology candidate NCX 434
  • 26 mag, 2010
    Alessandro Sidoli appointed President of Assobiotec for the 3-years period 2010-2012
    Bio3 Research Patent Granting in Mexico
    MAVI Sud attends Skin Nutrition, Cosmetic & Personal Care Industry Forum 2010
  • 05 mag, 2010
    Presented in Milan the Report “Biotechnology in Italy 2010”. The Italian biotech is young but rapidly growing
    Italy at Bio 2010
    NiKem Research Receives Authorization for Rodent Toxicology Studies
    bioPmed/Bioindustry Park Silvano Fumero signed a partnership agreement with Lyonbiopole
    Pooled phase 3 blood pressure results for NicOx’s naproxcinod presented at the American Society of Hypertension
  • 15 apr, 2010
    Siena Biotech’s news
    Polyphor Ltd and Axxam S.p.A. Announce Ion Channel Collaboration
    Adienne Pharma & Biotech: exclusive European marketing authorization throughout for the orphan medicinal product for human use Tepadina
    MolMed starts Phase III trial of NGR-hTNF in mesothelioma
    NiKem Research Receives Qualification for Bioanalysis of Clinical Samples
  • 15 mar, 2010
    Shire Announces FDA Approval of VPRIV for the treatment of Type 1 Gaucher disease
    Toscana Biomarkers announces Multiplex Assay System Research collaboration agreement with QuantiScientifics L.L.C.
    Promega – TOP agreement enables Live Animal Imaging for cancer studies
    FDA plans to discuss the New Drug Application (NDA) for NicOx’s naproxcinod
    Bio3 Research Patents Granting in the USA and Europe
    Lay Line Genomics re-launches AntiTrkA project for the treatment of chronic pain
  • 03 mar, 2010
    NAICONS announces research collaboration with sanofi-aventis
    Genzyme’s Thyrogen receives European Commission approval for broader indication in Thyroid Cancer patients
    Genextra further invest $25 million series B financing in Intercept Pharmaceuticals
    Mipomersen Phase 3 study in patients with Heterozygous Familial Hypercholesterolemia meets primary endpoint
    NicOx and Bausch + Lomb announce worldwide licensing agreement for NCX 116
  • 01 feb, 2010
    NicOx announces EMEA validation of naproxcinod MAA submission
    Fast Forward, Juvenile Diabetes Research Foundation and Axxam join forces to accelerate development of treatments for multiple sclerosis and Type 1 diabetes
    Lymphoma: to be tested the first anti-cancer vaccine fully “made in Italy”
    Piemontech will invest in two promising Piedmont-based biotech companies
    Genovax completes the selection of patients for the Phase I clinical study of its project GX301
    Adriacell develops CROMOC molecules, a new class of anti-cancer treatment products with the goal of blocking the growth of tumour cells.
    Newron completes enrolment in SERENA Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain
    NAICONS and NexThera transfer rights to NAI-­107, a new anti­MRSA antibiotic, to Sentinella Pharmaceuticals
    Newron reports positive Pre-IND Meeting with FDA and MHRA for its NCE NW-3509 as an add-on to antipsychotics in patients with schizophrenia
    IRB Syringa vulgaris biotech extracts granted Patent in the United States
  • 15 gen, 2010
    NicOx submits naproxcinod MAA to the EMEA
    DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler
    NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis